Page last updated: 2024-10-24

negative regulation of adipose tissue development

Definition

Target type: biologicalprocess

Any process that stops, prevents or reduces the frequency, rate or extent of adipose tissue development. [GO_REF:0000058, GOC:TermGenie, PMID:23081848]

Negative regulation of adipose tissue development is a complex biological process that involves a coordinated interplay of multiple factors, including transcription factors, signaling molecules, and epigenetic modifications. This process is crucial for maintaining energy homeostasis and preventing excessive fat accumulation. Here's a detailed description:

**1. Transcriptional Regulation:**
* **PPARγ (Peroxisome Proliferator-Activated Receptor gamma):** A master regulator of adipogenesis, PPARγ promotes the expression of genes involved in adipocyte differentiation and lipid storage. Negative regulation of adipose tissue development can involve suppression of PPARγ activity through various mechanisms:
* **Ligand Competition:** Molecules that bind to PPARγ and act as antagonists can block its activation.
* **Protein-Protein Interactions:** Proteins that interact with PPARγ can inhibit its transcriptional activity.
* **Post-translational Modifications:** Modifications like phosphorylation or acetylation can modulate PPARγ activity.
* **Other Transcription Factors:** Several other transcription factors, such as C/EBPα (CCAAT/enhancer binding protein alpha) and SREBP1 (sterol regulatory element binding protein 1), are involved in adipogenesis. Inhibiting their expression or activity can also negatively regulate adipose tissue development.

**2. Signaling Pathways:**
* **Insulin Signaling:** Insulin promotes adipocyte differentiation and lipid accumulation. Blocking insulin signaling, either at the receptor level or downstream, can inhibit adipose tissue development.
* **Wnt Signaling:** Wnt signaling has been implicated in both promoting and inhibiting adipogenesis, depending on the specific pathway involved. Inhibition of Wnt signaling can negatively regulate adipose tissue development.
* **AMPK (Adenosine Monophosphate-Activated Protein Kinase):** AMPK activation promotes fatty acid oxidation and inhibits lipogenesis, thereby contributing to negative regulation of adipose tissue development.
* **Adiponectin Signaling:** Adiponectin, an adipokine secreted from adipose tissue, has insulin-sensitizing and anti-inflammatory effects. Increased adiponectin signaling can indirectly promote negative regulation of adipose tissue development by improving insulin sensitivity and reducing inflammation.

**3. Epigenetic Modifications:**
* **DNA Methylation:** Modifications in DNA methylation patterns can affect gene expression and thus influence adipogenesis. Hypermethylation of genes involved in adipocyte differentiation can lead to their silencing, thereby inhibiting adipose tissue development.
* **Histone Modifications:** Changes in histone acetylation and methylation can alter chromatin structure and accessibility, influencing gene expression. Histone modifications that promote a closed chromatin state can suppress adipogenesis.

**4. Cellular Processes:**
* **Apoptosis:** Increased apoptosis (programmed cell death) of preadipocytes can limit the formation of new adipocytes.
* **Lipolysis:** Increased lipolysis (breakdown of stored fat) can reduce the size and number of adipocytes, contributing to negative regulation of adipose tissue development.

**5. Other Factors:**
* **Hormonal Influences:** Hormones like thyroid hormone, growth hormone, and glucocorticoids can influence adipogenesis. Dysregulation of these hormones can contribute to negative regulation of adipose tissue development.
* **Nutritional Status:** Diet and energy intake play a crucial role in regulating adipose tissue development. Calorie restriction and a diet low in saturated fats can promote negative regulation of adipose tissue growth.
* **Environmental Factors:** Factors like stress, sleep deprivation, and exposure to environmental toxins can also influence adipose tissue development and potentially contribute to negative regulation.

In summary, negative regulation of adipose tissue development is a complex process involving multiple cellular and molecular mechanisms that work together to maintain energy homeostasis and prevent excessive fat accumulation. Understanding these mechanisms is crucial for developing strategies to combat obesity and related metabolic diseases.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Poly [ADP-ribose] polymerase 1A poly [ADP-ribose] polymerase 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P09874]Homo sapiens (human)

Compounds (53)

CompoundDefinitionClassesRoles
niacinamidenicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.pyridine alkaloid;
pyridinecarboxamide;
vitamin B3
anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
1,5-dihydroxyisoquinoline1,5-dihydroxyisoquinoline: structure in first source

isoquinoline-1,5-diol : An isoquinolinol that is isoquinoline in which the hydrogens at positions 1 and 5 are replaced by hydroxy groups.
isoquinolinolEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
3-aminobenzamidebenzamides;
substituted aniline
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
4-amino-1,8-naphthalimide4-amino-1,8-naphthalimide: inhibits ADP-ribosylation; sometimes abreviated as 4-AN;benzoisoquinoline;
dicarboximide
phenanthridonephenanthridone : A member of the class of phenanthridines that is phenanthridine with an oxo substituent at position 6. A poly(ADP-ribose) polymerase (PARP) inhibitor, it has been shown to exhibit immunosuppressive activity.

phenanthridone: coal tar derivative; structure given in first source
lactam;
phenanthridines
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
immunosuppressive agent;
mutagen
5-aminoisoquinolinone5-aminoisoquinolinone: structure in first sourceisoquinolines
benzamidebenzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.benzamides
pj-34PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties.phenanthridines;
secondary carboxamide;
tertiary amino compound
angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent
1-hydroxyphthalazine1-hydroxyphthalazine: RN given refers to cpd with unspecified locants; do not confuse with cpd phthalazinol RN: 56611-65-5phthalazines
chlorthenoxazinchlorthenoxazin: RN given refers to parent cpd; structurebenzoxazine
isocarbostyrilisoquinolinone : An isoquinoline containing one or more oxo groups.isoquinolines
flavoneflavone : The simplest member of the class of flavones that consists of 4H-chromen-4-one bearing a phenyl substituent at position 2.

flavone: RN given refers to unlabeled cpd; structure given in first source
flavonesmetabolite;
nematicide
2,4(1h,3h)-quinazolinedione2,4(1H,3H)-quinazolinedione: structure given in first source
4-hydroxybenzamide
naphthalimidesNaphthalimides: Compounds with three fused rings that appear like a naphthalene fused to piperidone or like a benz(de)isoquinoline-1,3-dione (not to be confused with BENZYLISOQUINOLINES which have a methyl separating the naphthyl from the benzyl rings). Members are CYTOTOXINS.
4-fluorobenzamide4-fluorobenzamide: structure in first source
5-iodo-6-amino-1,2-benzopyrone
alantolactonealantolactone : A sesquiterpene lactone that is 3a,5,6,7,8,8a,9,9a-octahydronaphtho[2,3-b]furan-2-one bearing two methyl substituents at positions 5 and 8a as well as a methylidene substituent at position 3.

alantolactone: allergenic sesquiterpene lactone; crystalline mixture of alantolactones from group of sesquiterpenes; structure
naphthofuran;
olefinic compound;
sesquiterpene lactone
antineoplastic agent;
apoptosis inducer;
plant metabolite
4-aminobenzamidebenzamides
4-Methoxybenzamidebenzamides
3-methoxybenzamide
3',4'-dihydroxyflavone3',4'-dihydroxyflavone: inhibitors of arachidonic acid peroxidation
3,4-dihydro-5-methyl-1(2h)-isoquinolinone3,4-dihydro-5-methyl-1(2H)-isoquinolinone: structure given in first sourceisoquinolines
1-oxo-1,2,3,4-tetrahydroisoquinoline1-oxo-1,2,3,4-tetrahydroisoquinoline: structure given in first source
cyclo(alanylalanyl)
N-[4-[[[4-(4-methoxyphenyl)-4-oxanyl]methylamino]-oxomethyl]phenyl]-2-furancarboxamidearomatic amide;
furans
ha 1100HA 1100: intracellular calcium antagonist
apigeninChamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.trihydroxyflavoneantineoplastic agent;
metabolite
luteolin3'-hydroxyflavonoid;
tetrahydroxyflavone
angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
amentoflavonebiflavonoid;
hydroxyflavone;
ring assembly
angiogenesis inhibitor;
antiviral agent;
cathepsin B inhibitor;
P450 inhibitor;
plant metabolite
3',4',7-trihydroxyflavone3',4',7-trihydroxyflavone: from the Sudanese medicinal plant Albizia zygia; structure in first sourceflavones
adenosine diphosphate (hydroxymethyl)pyrrolidinedioldihydroxypyrrolidine;
purine ribonucleoside 5'-diphosphate
ag 14361benzimidazoles
gpi 6150
rucaparibAG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first sourceazepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound
antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
3,4-dihydro-5-(4-(1-piperidinyl)butoxy)-1(2h)-isoquinolinone
veliparibbenzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
olaparibcyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines
antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
niraparib2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide : A member of the class of indazoles that is 2H-indazole substituted by 4-(piperidin-3-yl)phenyl and aminocarbonyl groups at positions 2 and 7, respectively. It is a potent PARP1 inhibitor with IC50 of 3.2 nM.benzenes;
indazoles;
piperidines;
primary carboxamide
antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
niraparibniraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.

niraparib: structure in first source
2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamideantineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent
cep 26401pyridazines;
ring assembly
iwr-1 endoIWR-1-endo : A dicarboximide having an endo bridged phthalimide structure, substituted at nitrogen by a 4-(quinolin-8-ylcarbamoyl)benzoyl group.benzamides;
bridged compound;
dicarboximide;
quinolines
axin stabilizer;
Wnt signalling inhibitor
nms-p118NMS-P118: a PARP-1 inhibitor; structure in first source
g007-lkG007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source
nu 1025NU 1064: structure in first sourcephenols;
quinazolines
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
2-methyl-4(3h)-quinazolinone2-methyl-4(3H)-quinazolinone: from Bacillus cereus; structure given in first source
4-hydroxyquinazoline4-oxo-3,4-dihydroquinazoline: structure in first sourcequinazolines
1,4-Dihydrothieno[3,2-d]pyrimidin-4-oneorganic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
xav939XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.

XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source
(trifluoromethyl)benzenes;
thiopyranopyrimidine
tankyrase inhibitor
2-(4-methoxyphenyl)-1H-quinazolin-4-onequinazolines
bmn 673talazoparib: inhibits both PARP1 and PARP2; structure in first source
me0328ME0328: inhibits ARTD3; structure in first source
nvp-tnks656